Vacis

VACIS, a biotechnology and healthcare startup, is pioneering the future of vascular surgery with patient-specific blood vessels engineered for enduring performance and minimal complications. Founded in 2016, the company specializes in the creation of body-own blood vessels, focusing on developing in situ tissue-engineered blood vessels to offer innovative therapeutic options for vascular surgery. One of the main challenges in this field is the high rate of prosthetic vascular graft failure, leading to significant patient morbidity and increased healthcare costs. VACIS addresses this issue by providing patients with autologous graft vessels, characterized by sustained patency and fewer complications, thus necessitating fewer corrective interventions. The company's approach has attracted the attention of investors, with its Venture Round investment on 11 October 2019 from notable backers including NV Industriebank LIOF, Brightlands Venture Partners, and HTGF | High-Tech Gruenderfonds. Overall, VACIS is at the forefront of revolutionizing vascular surgery and elevating patient care with its innovative tissue engineering solutions.